PRostate Cancer Plasma Integrative Multi-modal Evaluation
Launched by SANTA CHIARA HOSPITAL · May 13, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PRostate Cancer Plasma Integrative Multi-modal Evaluation (PRIME) trial is studying a new blood test designed to help doctors understand advanced prostate cancer better. This test, called a liquid biopsy, looks at different materials found in the blood, such as DNA and proteins, to gather important information about the cancer. By analyzing these materials, researchers hope to improve how prostate cancer is diagnosed and treated, making it easier for healthcare providers to tailor therapies to individual patients.
To participate in this trial, men aged 65 to 74 who have been diagnosed with prostate cancer and are eligible for treatment can apply. Participants will need to give their consent to join the study. Throughout the trial, they can expect to have blood samples taken, which will be used to develop and refine the new test. This research could potentially lead to better management of prostate cancer in the future, benefiting not just the participants but many others facing this disease.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of prostate cancer
- • Eligible for prostate cancer pharmacological treatment
- • Given consent to study participation
- Exclusion Criteria:
- • - Histological diagnosis other than prostate cancer
About Santa Chiara Hospital
Santa Chiara Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and a focus on multidisciplinary collaboration, the hospital serves as a vital center for clinical research across various therapeutic areas. Leveraging state-of-the-art facilities and a team of experienced healthcare professionals, Santa Chiara Hospital aims to contribute to the development of new treatments and therapies, ensuring that patients have access to the latest advancements in medicine. Through rigorous adherence to ethical standards and regulatory guidelines, the hospital fosters a research environment that prioritizes patient safety and scientific integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Padova, , Italy
Trento, , Italy
Meldola, Forlì Cesena, Italy
Orbassano, Torino, Italy
Meldola, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported